Eaton Vance Management’s Marker Therapeutics MRKR Stock Holding History

Eaton Vance Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-821	Closed	-$8K	–	2369
2021 Q4	$8K	Hold	821	–	–	﹤0.01%	2573
2021 Q3	$14K	Hold	821	–	–	﹤0.01%	1695
2021 Q2	$23K	Hold	821	–	–	﹤0.01%	2397
2021 Q1	$18K	Buy	+821	New	+$18.8K	﹤0.01%	2128

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Eaton Vance Management's MRKR Position: Q1 2022 in Review

Eaton Vance Management sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 821 shares — an estimated $8K sold.

Eaton Vance Management first reported a position in MRKR in Q1 2021 and held it in 4 quarters. The position peaked at $23K in Q2 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Eaton Vance Management reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 821 Marker Therapeutics shares in Q1 2022, an estimated $8K.
Eaton Vance Management first reported a position in Marker Therapeutics in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's Marker Therapeutics position peaked at $23K in Q2 2021.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.